Specialists in biomolecules
This year’s ACR/ARHP meeting will be held in San Diego, California, on 3-8 November
All of Bioiberica’s communications will be presented on November 6, the day dedicated to osteoarthritis research
The 2017 Annual Meeting of the American College of Rheumatology will have an unprecedented educational content, with more than 450 scientific sessions. These sessions include updates on some of the most relevant advances worldwide in research and clinical applications for rheumatologists.
Bioiberica will actively participate in the meeting, presenting four clinical research communications in osteoarthritis:
All these studies will be presented in separate sessions that will take place on November 6, the day dedicated to education in osteoarthritis.
These studies are being carried out thanks to the collaboration between Bioiberica and various universities and research centers which are developing the most advanced clinical essays in osteoarthritis biomarkers. Their findings will allow us to determine the best treatments for osteoarthritis patients. As Dr Marta Herrero, head of clinical development at Bioiberica’s Human Health Division, commented, these studies represent “a clear example of Bioiberica’s commitment to clinical research in osteoarthritis”.
Bioiberica is a company with more than 40 years of experience under their belt in the identification and production of biomolecules for the pharmaceutical industry. It is the only international firm that has developed three chondroprotective molecules: glucosamine, hyaluronic acid, and chondroitin sulfate, of which it is the leading producer worldwide.